Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för PF-00477736. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2015-11-05

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.

Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G.

J Hematol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13045-015-0206-5

Bibliografisk träff 2015-11-01

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.5954

Bibliografisk träff 2015-02-01

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.2583

Bibliografisk träff 2014-11-11

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S.

Leuk Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.leukres.2014.10.009

Bibliografisk träff 2014-08-07

Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.

Bryant C, Rawlinson R, Massey AJ.

BMC Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-14-570

Bibliografisk träff 2014-05-16

Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.

Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, Chou A, Biankin AV, Grimmond SM, Australian Pancreatic Cancer Genome Initiative, Brown MP, Khanna KK.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-14-0048

Bibliografisk träff 2013-07-02

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.

Fang DD, Cao J, Jani JP, Tsaparikos K, Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, Zhu Z, Gu Y, Los G, Hostomsky Z, Vanarsdale T.

Front Med · evaluation study; journal article · DOI 10.1007/s11684-013-0270-6

Bibliografisk träff 2009-07-07

PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.

Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K, Christensen JG.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-08-3272

Bibliografisk träff 2008-09-01

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.

Ashwell S, Janetka JW, Zabludoff S.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.17.9.1331